Purity CAS 71125-38-7 Meloxicam Pharmaceutical Grade Meloxicam Anti-Inflammatory Meloxicam
Product Description
Product Details
|
Product Name
|
Meloxicam |
|
Appearance
|
Yellow powder |
|
Assay
|
99%min, 98.0% --101.0% |
|
Test
|
HPLC
|
|
Certificate
|
ISO 9001
|
|
CAS
|
71125-38-7 |
| MF |
C14H13N3O4S2 |
| Storage Temperature |
Cool Dry Place
|
1. Analgesic effect Like other NSaids, Meloxicam is mainly used for mild and moderate chronic dull pain, such as neuralgia and joint pain. It has a strong and lasting analgesic effect on experimental rat inflammatory pain. In experimental Lewis rats with RA, the dose of 0.063 ~ 0.5mg·kg-1, once a day, oral administration for 21 days, not only effective on the redness and swelling of rat hind paw and bone and cartilage damage, but also has a strong and lasting analgesic effect on inflammation and pain, the oral dose of up to 10mg·kg-1, no effect on the central nervous system Similar to indomethacin, meloxicam had no analgesic effect on visceral pain.
2. Antipyretic effect Meloxicam can reduce the body temperature of febrile persons, but has little effect on normal body temperature. For example, in the anti-inflammatory dose range, meloxicam had no effect on normal body temperature in rats, but reduced yeast-induced fever. Endotoxin was injected intravenously in rats to induce fever, and meloxicam 0.1,0.3 or 0.5mg·kg-1 was injected intravenously twice a week, which showed obvious cooling effect. The optimal antipyretic dose was 0.3mg·kg-1. Twice a week.
3. Anti-inflammatory effects were observed in animal inflammatory models (mainly the rat posterior paw edema model induced by carrageenan and white clay) and the rat granuloma model implanted with cotton ball; Both carcarina-induced pleurisy and Mycobacterium tuberculosis induced arthritis with liquid paraffin as adjuvant) and meloxicam showed strong anti-inflammatory activity. Chemicalbook induced pleurisy. Unlike indomethacin, meloxicam reduces pleurisy secretion and inhibits leukocyte migration. In rat pleurisy, meloxicam inhibited the biosynthesis of prostaglandin E2(PGE2) by twice as much as piroxicam and eight times as much as diclofenac, respectively. Meloxicam was twice as effective as piroxicam and more than 10 times as effective as diclofenac in peritonitis in mice. In male Lewis rats with experimental RA, meloxicam, piroxicam, diclofenac or tenidap (tenidap) were administered orally once a day for 21 days to observe the enlargement of the rat posterior paw, bone and cartilage injury of the hind paw, increase in spleen weight, erythrocyte settlement rate and changes in serum protein components. It was found that all the above drugs could inhibit the rat posterior paw enlargement and the rat posterior paw enlargement caused by secondary reactions. The dose of pyloxicam was twice that of Meloxicam, while the dose of diclofenac and tenidapol was 3.5 and 60 times that of Meloxicam, respectively. A lower daily dose of meloxicam is required to inhibit RA-induced bone and cartilage damage, and pyloxicam is 4 times greater. The doses of diclofenac and tenidapol, which inhibit the swelling of rat hind PAWS, had little effect on bone and cartilage damage. The dose of piroxicam was 3 ~ 4 times that of meloxicam for the series of symptom changes and dose-dependent correction effect in RA rats. Diclofenac and Tenidapol did not produce a comparable effect.
Application&Function
For rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, soft tissue injury pain, etc
Specification
Audited Supplier 
){kind=link}
){kind=link}